Insmed (INSM) Other financing activities (2013 - 2026)
Insmed (INSM) posted quarterly Other financing activities of $30.3 million for Q1 2026, up 2.05% year-over-year from $29.7 million in Q1 2025, and down 12.48% quarter-over-quarter from $34.6 million in Q4 2025.
Insmed (INSM) Other financing activities (2013 - 2026) Analysis & Trends
Insmed's Other financing activities history runs 14 years deep, the most recent figure standing at $30.3 million for Q1 2026.
- In Q1 2026, Other financing activities rose 2.05% year-over-year to $30.3 million; the TTM figure through Mar 2026 stood at $136.3 million (down 1.85% YoY), while the FY2025 annual figure was $135.7 million, up 19.85% from the prior year.
- Other financing activities for Q1 2026 stood at $30.3 million, down from $34.6 million in the prior quarter.
- The five-year high for Other financing activities was $68.6 million in Q2 2024, with the low at $1.1 million in Q1 2023.
- The 5-year median for Other financing activities is $7.6 million (2023), against an average of $18.7 million.
- The sharpest annual moves came in 2023 and 2024: Other financing activities tumbled 83.29% in 2023, then surged 1048.23% in 2024.
- Insmed's Other financing activities stood at $2.2 million in 2022, then soared by 251.73% to $7.6 million in 2023, then soared by 79.94% to $13.7 million in 2024, then soared by 152.07% to $34.6 million in 2025, then slipped by 12.48% to $30.3 million in 2026.
- Business Quant data shows INSM's Other financing activities at $30.3 million in Q1 2026, $34.6 million in Q4 2025, and $34.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.01 Mn |
| Jun 30, 2026 | 28.01 Mn |
| Mar 31, 2026 | 30.31 Mn |
| Mar 31, 2026 | 30.31 Mn |
| Dec 31, 2025 | 34.64 Mn |
| Dec 31, 2025 | 34.64 Mn |
| Sep 30, 2025 | 34.41 Mn |
| Sep 30, 2025 | 34.41 Mn |
| Jun 30, 2025 | 36.97 Mn |
| Jun 30, 2025 | 36.97 Mn |
| Mar 31, 2025 | 29.70 Mn |
| Mar 31, 2025 | 29.70 Mn |
| Dec 31, 2024 | 13.74 Mn |
| Dec 31, 2024 | 13.74 Mn |
| Sep 30, 2024 | 26.88 Mn |
| Sep 30, 2024 | 26.88 Mn |
| Jun 30, 2024 | 68.57 Mn |
| Jun 30, 2024 | 68.57 Mn |
| Mar 31, 2024 | 4.05 Mn |
| Mar 31, 2024 | 4.05 Mn |